Risk for second primary cancer higher in patients who smoked prior to first cancer
the ONA take:
A significant behavior that increases the risk of developing cancer is cigarette smoking. This fact has been proven in countless studies, and a recent pooled analysis of five prospective cohort studies indicates that the cancer risk goes beyond developing a first primary cancer.
The analysis shows that patients who smoked 20 or more cigarettes a day prior to a diagnosis of lung (stage I), bladder, kidney, or head and neck cancer were at increased risk of developing a second primary smoking-associated cancer compared with patients who had never smoked and had survived the same first cancers. The researchers note the second primary cancers are not metastases of the first cancer, but distinct new malignancies.
Smokers who smoked fewer than 20 cigarettes per day and former smokers who had quit before their first cancer diagnosis also were at higher risk of developing a second cancer. This is the first study to explore the risk of second primary cancers in current smokers.
Although further research is needed to assess the association between smoking after a first cancer and second cancer risk, these results further support encouraging smoking cessation to all patients who smoke.
A significant behavior that increases the risk of developing cancer is cigarette smoking.
Results of a federally-funded pooled analysis of five prospective cohort studies indicate that cigarette smoking prior to the first diagnosis of lung (stage I), bladder, kidney or head and neck cancer increases risk of developing a second smoking-associated cancer. This is the largest study to date exploring risk of second cancers among current smokers.
An analysis of five large, prospective cohort studies indicates that lung (stage I), bladder, kidney and head and neck cancer survivors who smoked 20 or more cigarettes a day prior to their cancer diagnoses have an up to five-fold higher risk of developing a second smoking-associated cancer compared to survivors of the same cancers who never smoked.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|